CEP55 and prostate cancer: Finally, two lipid metabolism subtypes, LMscore-high and LMscore-low, were identified based on this GC cohort, and the top five genes were CAV1, PALM, PCDH7, C14orf132, and CEP55. These DEGs have been validated to regulate lipid metabolism in cell renal cell carcinoma1 (Zhang et al., 2021), prostate cancer (Vykoukal et al., 2020) and colon cancer (Jeffery et al., 2016), which indicated that these DEGs may be potential prognostic biomarkers and therapeutic targets for GC.